Clover Biopharmaceuticals, Ltd., A Global Clinical-Stage Biotechnology Company, Announced The First Participants Have Been Dosed In A Phase 1 Clinical Trial To Assess The Safety And Immunogenicity Of Several Formulations Of Scb-2020S. Scb-2020S Is A Second Generation, Potentially Broadly Protective Covid-19 Vaccine Candidate Based On A Chimeric Beta And Prototype Trimeric Sars-Cov-2 S-Protein, Preserving Potential Neutralization Epitopes Across Multiple Variants Of Concern (Vocs) Of Sars-Cov-2, Including Omicron. Clover Intends To Explore How The Scb-2020S Construct Could Further Expand The Breadth Of Vaccine-Induced Neutralizing Antibodies To Address The Existing And Potential New Variant Strains Of The Sars-Cov-2 Virus.
